Roche picks up a speedy nod in China as regulators follow through on plans for a fast 48 new drug OKs
Chinese regulatory authorities are following through with their plan to rush along a slate of new drug approvals. And Roche finds itself near the front of the line formed to benefit from that new trend.
Overnight Roche reported that the China National Drug Administration had followed up with a green light for Roche to start selling Alecensa as a frontline therapy for advanced cases of ALK-positive non-small cell lung cancer. Roche heralded an OK that arrived just 8 and 9 months after the EMA and FDA flagged the drug through for frontline use following new data underscoring its efficacy in treating patients compared to a standard of care.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.